$TYRA
Tyra Biosciences, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023060276 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.957M $0.00
YoY Change 7.34% -100.0%
% of Gross Profit
Research & Development $20.68M $19.27M
YoY Change 98.82% 76.56%
% of Gross Profit
Depreciation & Amortization $102.0K $100.0K
YoY Change 24.39% -99.88%
% of Gross Profit
Operating Expenses $25.63M $23.96M
YoY Change 70.69% 75.62%
Operating Profit -$23.96M
YoY Change 75.62%
Interest Expense $2.815M $2.820M
YoY Change 30.57% 149.34%
% of Operating Profit
Other Income/Expense, Net -$11.00K $2.811M
YoY Change -66.67% 147.45%
Pretax Income -$22.83M -$21.15M
YoY Change 77.05% 69.08%
Income Tax
% Of Pretax Income
Net Earnings -$22.83M -$21.15M
YoY Change 77.05% 69.09%
Net Earnings / Revenue
Basic Earnings Per Share -$0.49
Diluted Earnings Per Share -$0.53 -$0.49
COMMON SHARES
Basic Shares Outstanding 43.06M 43.01M
Diluted Shares Outstanding 42.87M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $203.5M $215.7M
YoY Change -19.01% -18.05%
Cash & Equivalents $58.01M $215.7M
Short-Term Investments $145.5M
Other Short-Term Assets $8.202M $9.000M
YoY Change 35.01% 111.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $211.7M $224.6M
YoY Change -17.73% -16.02%
LONG-TERM ASSETS
Property, Plant & Equipment $8.154M $1.147M
YoY Change 657.1% 0.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.032M $5.345M
YoY Change 38.67% 38.04%
Total Long-Term Assets $14.19M $13.73M
YoY Change 59.52% 61.24%
TOTAL ASSETS
Total Short-Term Assets $211.7M $224.6M
Total Long-Term Assets $14.19M $13.73M
Total Assets $225.9M $238.4M
YoY Change -15.15% -13.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.662M $2.308M
YoY Change 307.16% -15.98%
Accrued Expenses $10.67M $7.800M
YoY Change 134.22% 184.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.33M $10.15M
YoY Change 168.95% 84.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.262M $77.00K
YoY Change 3605.33% -65.93%
Total Long-Term Liabilities $6.262M $77.00K
YoY Change 3605.33% -65.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.33M $10.15M
Total Long-Term Liabilities $6.262M $77.00K
Total Liabilities $21.60M $16.19M
YoY Change 158.56% 96.72%
SHAREHOLDERS EQUITY
Retained Earnings -$164.8M -$142.0M
YoY Change 72.2% 71.5%
Common Stock $368.7M $364.2M
YoY Change 4.3% 3.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $204.3M $222.2M
YoY Change
Total Liabilities & Shareholders Equity $225.9M $238.4M
YoY Change -15.15% -13.63%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$22.83M -$21.15M
YoY Change 77.05% 69.09%
Depreciation, Depletion And Amortization $102.0K $100.0K
YoY Change 24.39% -99.88%
Cash From Operating Activities -$13.53M -$17.15M
YoY Change 12.95% 40.44%
INVESTING ACTIVITIES
Capital Expenditures $603.0K $90.00K
YoY Change 2771.43% -287.5%
Acquisitions
YoY Change
Other Investing Activities -$143.8M
YoY Change
Cash From Investing Activities -$144.4M -$90.00K
YoY Change 687700.0% 87.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 324.0K 460.0K
YoY Change 10700.0% 26.37%
NET CHANGE
Cash From Operating Activities -13.53M -17.15M
Cash From Investing Activities -144.4M -90.00K
Cash From Financing Activities 324.0K 460.0K
Net Change In Cash -157.6M -16.78M
YoY Change 1213.94% 41.06%
FREE CASH FLOW
Cash From Operating Activities -$13.53M -$17.15M
Capital Expenditures $603.0K $90.00K
Free Cash Flow -$14.14M -$17.24M
YoY Change 17.78% 41.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001863127
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40800
dei Entity Registrant Name
EntityRegistrantName
TYRA BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1476348
dei Entity Address Address Line1
EntityAddressAddressLine1
2656 State Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
dei City Area Code
CityAreaCode
619
dei Local Phone Number
LocalPhoneNumber
728-4760
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
TYRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43058747
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
215652000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251213000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8978000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6075000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
224630000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
257288000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1147000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1077000
CY2023Q3 tyra Right Of Use Asset
RightOfUseAsset
6236000
CY2022Q4 tyra Right Of Use Asset
RightOfUseAsset
2466000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5345000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4350000
CY2023Q3 us-gaap Assets
Assets
238358000
CY2022Q4 us-gaap Assets
Assets
266181000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2308000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1145000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
148000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
140000
CY2023Q3 tyra Accrued And Other Related Parties
AccruedAndOtherRelatedParties
0
CY2022Q4 tyra Accrued And Other Related Parties
AccruedAndOtherRelatedParties
59000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7691000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4416000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10147000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5701000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5964000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2482000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
77000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
169000
CY2023Q3 us-gaap Liabilities
Liabilities
16188000
CY2022Q4 us-gaap Liabilities
Liabilities
8352000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43055393
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42634459
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42928884
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42353550
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
364166000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
353521000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-142000000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95696000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
222170000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
257829000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
238358000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
266181000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19271000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10915000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41841000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32608000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
0
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
173000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
0
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
570000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4692000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2730000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12470000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11301000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
23963000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
13645000
us-gaap Operating Expenses
OperatingExpenses
54311000
us-gaap Operating Expenses
OperatingExpenses
43909000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23963000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13645000
us-gaap Operating Income Loss
OperatingIncomeLoss
-54311000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43909000
CY2023Q3 tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
2816000
CY2022Q3 tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
1131000
tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
8035000
tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
1496000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-28000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2811000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1136000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8007000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1479000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-21152000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-12509000
us-gaap Net Income Loss
NetIncomeLoss
-46304000
us-gaap Net Income Loss
NetIncomeLoss
-42430000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42868340
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42868340
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41997195
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41997195
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42619075
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42619075
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41777052
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41777052
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
301737000
CY2022Q1 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
238000
CY2022Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
63000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3972000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14826000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
291184000
CY2022Q2 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
34000
CY2022Q2 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
42000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2688000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-15095000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
278853000
CY2022Q3 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
356000
CY2022Q3 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
37000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1019000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-12509000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
267756000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
257829000
CY2023Q1 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
376000
CY2023Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
32000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2433000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
248790000
CY2023Q2 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
494000
CY2023Q2 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
31000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2529000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
9000
tyra Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
93000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13272000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
238572000
CY2023Q3 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
343000
CY2023Q3 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
30000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4377000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-21152000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
222170000
us-gaap Net Income Loss
NetIncomeLoss
-46304000
us-gaap Net Income Loss
NetIncomeLoss
-42430000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
251000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
214000
us-gaap Share Based Compensation
ShareBasedCompensation
9339000
us-gaap Share Based Compensation
ShareBasedCompensation
7679000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
3910000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
5945000
CY2023Q3 tyra Accounts Payable Accrued Expenses And Other Liabilities Related Party Transactions
AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions
0
CY2022Q3 tyra Accounts Payable Accrued Expenses And Other Liabilities Related Party Transactions
AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions
17000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4293000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2150000
tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
-280000
tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
24000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36607000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38305000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
167000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
538000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-167000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-538000
tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
1213000
tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
629000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1213000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
629000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35561000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38214000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
252213000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
302425000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
216652000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
264211000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
215652000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263211000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
216652000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
264211000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4004000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1556000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
146000
tyra Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
142000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-08-02
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
1000000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1000000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1853000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1538000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
706000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
461000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1147000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1077000
CY2023Q3 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
300000
CY2022Q3 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
200000
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2403000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2854000
CY2023Q3 tyra Accrued Research And Development
AccruedResearchAndDevelopment
4753000
CY2022Q4 tyra Accrued Research And Development
AccruedResearchAndDevelopment
1028000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
255000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
94000
CY2023Q3 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
280000
CY2022Q4 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
440000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7691000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4416000
CY2023Q3 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
8110570
CY2022Q4 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
5890869
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13126816
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10989684
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5890869
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.91
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13492000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2883689
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.32
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
364547
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
299441
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.29
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8110570
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
39978000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2721726
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.07
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
19786000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8110570
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
39978000
CY2023Q3 tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-2107
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4377000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1019000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9339000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7679000
tyra Forfeitures Resulted In The Reversal Of Compensation Expense
ForfeituresResultedInTheReversalOfCompensationExpense
100000
tyra Forfeitures Resulted In The Reversal Of Compensation Expense
ForfeituresResultedInTheReversalOfCompensationExpense
1100000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
42300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2023Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
100000
CY2022Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
100000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
400000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
400000
CY2023Q3 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
124644
CY2022Q4 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
277081
CY2023Q3 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
100000
CY2022Q4 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
200000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-21152000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-12509000
us-gaap Net Income Loss
NetIncomeLoss
-46304000
us-gaap Net Income Loss
NetIncomeLoss
-42430000
CY2023Q3 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
43020965
CY2022Q3 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
42646810
us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
42822677
us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
42614902
CY2022Q3 tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-209421
tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-2762
tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-330928
CY2023Q3 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-150518
CY2022Q3 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-440194
tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-200840
tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-506922
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42868340
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42868340
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41997195
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41997195
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42619075
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42619075
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41777052
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41777052
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8237079
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6444057
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
800000
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
227000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
83000
us-gaap Operating Lease Cost
OperatingLeaseCost
473000
us-gaap Operating Lease Cost
OperatingLeaseCost
239000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
19000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
21000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
39000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
60000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
19000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
16000
us-gaap Variable Lease Cost
VariableLeaseCost
53000
us-gaap Variable Lease Cost
VariableLeaseCost
46000
CY2023Q3 us-gaap Lease Cost
LeaseCost
265000
CY2022Q3 us-gaap Lease Cost
LeaseCost
120000
us-gaap Lease Cost
LeaseCost
565000
us-gaap Lease Cost
LeaseCost
345000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
76000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
717000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
827000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
852000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
877000
CY2023Q3 tyra Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
5667000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9016000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2904000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6112000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
148000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5964000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y1M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0803
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065

Files In Submission

Name View Source Status
0000950170-23-060276-index-headers.html Edgar Link pending
0000950170-23-060276-index.html Edgar Link pending
0000950170-23-060276.txt Edgar Link pending
0000950170-23-060276-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tyra-20230930.htm Edgar Link pending
tyra-20230930.xsd Edgar Link pending
tyra-ex10_1.htm Edgar Link pending
tyra-ex31_1.htm Edgar Link pending
tyra-ex31_2.htm Edgar Link pending
tyra-ex32_1.htm Edgar Link pending
tyra-ex32_2.htm Edgar Link pending
tyra-20230930_def.xml Edgar Link unprocessable
tyra-20230930_lab.xml Edgar Link unprocessable
tyra-20230930_pre.xml Edgar Link unprocessable
tyra-20230930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
tyra-20230930_cal.xml Edgar Link unprocessable